Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104182 · ClinicalTrials.gov registry record · Phase 3
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
A Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 503
- Enrollment target
- 20
- Study locations
NCT00104182: Completed Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
NCT00104182 is a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 503 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00104182, a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 503 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin once a day (evening) when added to treatment with oral antidiabetic drugs in patients with Type 2 diabetes.
Conditions Studied
Interventions
- DRUG insulin NPH
- DRUG insulin detemir
Study Locations (20)
California
- Novo Nordisk Investigational Site - Anaheim
- Novo Nordisk Investigational Site - Concord
- Novo Nordisk Investigational Site - Fullerton
- Novo Nordisk Investigational Site - La Jolla
- Novo Nordisk Investigational Site - Los Angeles
- Novo Nordisk Investigational Site - Orange
- Novo Nordisk Investigational Site - Poway
Arizona
- Novo Nordisk Investigational Site - Mesa
- Novo Nordisk Investigational Site - Phoenix
Massachusetts
- Novo Nordisk Investigational Site - Fall River
- Novo Nordisk Investigational Site - Waltham
New York
- Novo Nordisk Investigational Site - Lewiston
- Novo Nordisk Investigational Site - Williamsville
Alabama
- Novo Nordisk Investigational Site - Birmingham
Colorado
- Novo Nordisk Investigational Site - Denver
Florida
- Novo Nordisk Investigational Site - Lake Mary
Illinois
- Novo Nordisk Investigational Site - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 503 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
What the finished NCT00104182 record still lists
NCT00104182 is an interventional study that assigns participants to a tested intervention. The registered 503 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which insulin NPH is the first listed.
NCT00104182 names 20 study sites across 11 states, led by California, Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00104182 about?
NCT00104182 is a clinical study titled "Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes". This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin once a day (evening) when added to treatment with oral antidiabetic drugs in patients with Type 2 diabetes.
What is the current status of trial NCT00104182?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 503 participants. The study started on 2005-02. Estimated completion is 2006-02.
What conditions does trial NCT00104182 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes.
What interventions are being tested in trial NCT00104182?
The interventions under investigation include: insulin NPH (DRUG), insulin detemir (DRUG).
Who is sponsoring clinical trial NCT00104182?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104182 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00104182's enrollment target sits among peer trials
503 77th of 348 higher than 272 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05143931 · 503 participants · NA
Avoid and Resist Strategies for Weight Management
- NCT05846282 · 504 participants · NA
Students Rising Above: Offsetting the Health and Mental Health Costs of Resilience
- NCT06072131 · 504 participants · Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
- NCT06736522 · 504 participants · NA
Future Leaders Program: Testing a Youth Leadership, Engagement, and Mindfulness Program
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia